Stocks to Buy

Identifying winning stocks requires more than scanning headlines. InvestorPlace analysts focus on long-term themes, market timing, and structural shifts shaping where capital is flowing next, highlighting stocks positioned to benefit from those trends.

6 Software Stocks to Buy Now

Six software stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an "A" ("strong buy") or "B" overall ("buy").

5 Stocks With Strong Earnings Surprises — OSTK REGI CRTO BRE FTEK

This week, these five stocks have the best ratings in Earnings Surprises, one of the eight Fundamental Categories on Portfolio Grader.

NCFT: Here’s What You Need to Know About Norcraft

If the market is bullish, homes are being purchased and remodeled and interest rates remain low. However, when those circumstances change, investors might move towards companies that make a profit they can understand.

4 Reasons to Buy China Travel Stocks Before Spring

The bulk of Spring Festival spending is tied to traveling, making China travel stocks a good investment. Here are four reasons why travel stocks in China are expected to perform well.

AAL Stock: American Airlines’ Absurd Strategy Reaping Billions

One opportunistic, wacky gamble has American Airlines (AAL) stock looking like a strong buy as oil prices fall to multi-year lows.

Dunkin’ Brands Is Serving Up Profits

Big expansion plans plus new inroads in the growing niche of “fast casual” dining are making DNKN a hot stock on the menu.

10 Best S&P 500 Stocks of 2014

The best stocks in the S&P 500 this year were mostly powered by consumer spending, though healthcare made itself heard too.

Today’s Revenue Miss is an Opportunity for FedEx (FDX) Stock

FedEx (FDX) stock falls in early trading today after second-quarter earnings and revenue missed expectations, but don't read into those numbers too deeply.

11 Biotechnology Stocks to Buy Now

This week, 11 biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").

7 Semiconductor Stocks to Buy Now

The grades of seven semiconductor stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an "A" ("strong buy") or "B" overall ("buy") rating.

10 Best “Strong Buy” Stocks — HBI UEIC AMBA and more

This week, these ten stocks, all currently earning A's ("strong buy") on Portfolio Grader, have the best year-to-date performance.

5 Stocks With Strong Earnings Momentum — KNSY REGI BELFB STV BCR

This week, these five stocks have the best ratings in Earnings Momentum, one of the eight Fundamental Categories on Portfolio Grader.

4 Service Stocks to Buy Now

The grades of four service stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an "A" ("strong buy") or "B" overall ("buy") rating.

4 Auto Parts Stocks to Buy Now

The grades of four auto parts stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an "A" ("strong buy") or "B" overall ("buy") rating.

4 Specialty Retail Stocks to Buy Now

This week, four specialty retail stocks are improving their overall rating on Portfolio Grader. Each of these rates an "A" ("strong buy") or "B" overall ("buy").

Best Selling Video Games of 2014

With the year almost over and most major titles released, it's time to look back at the best-selling video games of 2014.

The 5 Best ETFs to Buy for 2015

The five best ETFs for new investment in 2015 include funds that protect against U.S. volatility, exploit weakness in Russia and South America, and are prepared for a rebound in the domestic energy market.

AA: Alcoa Is Firing Up Its Margins

Alcoa remains a "buy" and is a bedrock pick for any portfolio. What's more, there's a good chance that AA stock is oversold here and has some upside potential even in these depressed commodities markets.

Novartis Stock: RX for Your Portfolio

Novartis is a global drug giant positioned to profit from Obamacare, demographic trends and exciting new drugs in the pipeline. With a huge market cap and several best-selling treatments in its portfolio, Novartis is a long-term bet on the continuing expansion of the health care sector.